Pfizer (NYSE: PFE) and Eli Lilly and Company (NYSE: LLY) represent two sharply different investment cases within the pharmaceutical sector, appealing to entirely different types of investors.
Pfizer has seen its valuation compress significantly in recent years, effectively repositioning the stock as a value and income play that attracts investors focused on yield and stability.
The stock trades at approximately 8.7x trailing adjusted earnings and carries a low sales multiple of 2.2x, placing it well below many of its large-cap pharmaceutical peers on a valuation basis.
A quarterly dividend of $0.43 per share, equivalent to $1.72 annually, translates into a dividend yield of approximately 7%, which remains a central pillar of the investment thesis for income-focused shareholders.
The key pressure on Pfizer stems from the continued normalization of its COVID-19 franchise, with the company expecting revenue from those products to decline by approximately $1.5 billion in 2026.
An additional $1.5 billion in negative revenue impact is anticipated in 2026 from products facing generic or biosimilar competition following the loss of patent or regulatory exclusivity.
Longer-term concerns center on flagship drugs including Eliquis and Ibrance, both of which face the prospect of losing exclusivity protection, putting further pressure on the company to rebuild its revenue base.
Pfizer is pursuing a position in the obesity-drug market through its acquisition of Metsera and a broader GLP-1 pipeline, though it enters a market where Eli Lilly and Novo Nordisk A/S (NYSE: NVO) already command significant commercial scale.
Eli Lilly, by contrast, has built a powerful growth narrative around its diabetes and weight-loss drug portfolio, with first-quarter revenues jumping 56% and the company subsequently raising its full-year revenue guidance.
Lilly is investing heavily in manufacturing capacity to support surging demand for its obesity medicines, a move that may weigh on near-term free cash flow but is designed to sustain the company’s long-term growth trajectory.
The premium attached to Lilly’s stock reflects those elevated expectations, with shares trading at roughly 40.7x trailing earnings, 14.3x sales, and 29.3x EV/EBITDA, metrics that leave little room for execution shortfalls.
Blockbuster drugs including Mounjaro and Zepbound account for a significant portion of Lilly’s total revenue, creating concentration risk should those products face pricing pressure, competition, or future exclusivity challenges.
On hedge fund positioning, 132 hedge funds held stakes in Lilly in the first quarter, a slight decline from 137 the prior quarter, according to the Insider Monkey database.
Fisher Asset Management, Adage Capital Management, and AQR Capital Management increased their Lilly positions by 6%, 15%, and 69%, respectively, signaling continued institutional confidence in the growth story.
Pfizer was held by 83 hedge fund portfolios at the end of the first quarter, up from 81 in the prior quarter, with Fisher Asset Management, Marshall Wace, and Unisphere Establishment increasing their positions by 103%, 28%, and 266%, respectively.
As of July 15, 2026, approximately 10.28 million Lilly shares were sold short, equivalent to 1.09% of the public float, while Pfizer carried short interest equivalent to 2.89% of its float as of June 30.
Those figures indicate that neither stock is under exceptionally heavy short pressure, though short sellers carry a comparatively larger position in Pfizer relative to float.
Ultimately, Pfizer’s roughly 7% dividend yield and depressed valuation offer a meaningful income proposition, while Lilly’s expanding obesity and diabetes franchise provides a compelling growth runway for investors with a higher risk tolerance.
